Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ravoxertinib hydrochloride is an orally bioavailable and selective inhibitor for ERK kinase activity (IC50: 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively).
Description | Ravoxertinib hydrochloride is an orally bioavailable and selective inhibitor for ERK kinase activity (IC50: 6.1 nM and 3.1 nM for ERK1 and ERK2, respectively). |
Targets&IC50 | p-RSK:12 nM, ERK2:3.1 nM, ERK1:6.1 nM |
In vitro | Ravoxertinib inhibits p90RSK (IC50: 12 nM) [1]. Ravoxertinib is highly selective for ERK1 and ERK2 (biochemical potency: 1.1 nM and 0.3 nM, respectively) [2]. |
In vivo | Ravoxertinib (10 mg/kg; p.o.; in CD-1 mice) is sufficient to achieve the desired target coverage for at least 8 h [1]. Ravoxertinib (p.o.; daily) causes significant single-agent activity in multiple in vivo cancer models, including KRAS-mutant and BRAF-mutant human xenograft tumors in mice [2]. |
Synonyms | GDC-0994 (hydrochloride) |
Molecular Weight | 477.32 |
Formula | C21H19Cl2FN6O2 |
CAS No. | 2070009-58-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (209.50 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Ravoxertinib hydrochloride 2070009-58-2 MAPK ERK GDC0994 GDC 0994 GDC-0994 (hydrochloride) GDC-0994 Ravoxertinib Hydrochloride inhibitor inhibit